Summer Sale
50% off Premium Yearly
00days
00hrs
00mins
00secs
NYSE:ABBV
AbbVie Inc. (ABBV)
217.00
+0.51 (0.24%)
as of Jun 18, 2026, 11:37:08 pm Market Open.
205 watching
Financials 
Technical Analysis 0
COMMENT
They have done well recently but he is looking for companies with longer term potential and expiry dates for drug patents. Should have good pipelines. Prefers diabetic care companies since this disease is on the rise. eg. Eli Lilly or Novo Nordisk. Astra Zeneca has a good pipeline in oncology drugs.
SELL
Great dividend, low valuation at 10x, and growing well, but he grabbed an exit point, as 43% of revenue comes from a drug going off patent next year. Pricing pressures mean that ABBV will see a decline in revenues and cashflows. Did well, but time to leave in favour of companies well off their highs.
0
;fill-opacity:1;'/%3e%3cpath%20d='M31%2018.6001V30H8V18.6001L14.1334%2022.4334L19.4999%2014L24.8669%2022.4334L31%2018.6001Z'%20fill='%23EE5432'%20style='fill:%23EE5432;fill:color(display-p3%200.9340%200.3310%200.1956);fill-opacity:1;'/%3e%3c/svg%3e){kind=small}
Premium contentPAST TOP PICK
BUY
It's done extremely well for him, but he's watching this carefully. Trades under 10x earnings and pays a 4% dividend. It's been growing well on their very successful Humera drug, but that goes off-patent in 2023. So, ABBV is working hard to fill that gap. They have a few promising drugs ramping up, but they will need to ramp up to the $10 billion range to fill Humera's shoes. A few years ago, they bought Botox which long-term will be good for ABBV, despite a slowdown during Covid. He still likes ABBV, but is keeping an eye on it in case earnings stall.
Gordon ReidOwned
0
PAST TOP PICK
(A Top Pick Feb 11/21, Up 40%) Still likes it. Clever acquisitions, which have started to backfill their R&D pipeline. Two of their next generation drugs are really taking the place of those coming off patent, and market is rewarding them for that. Technical breakout this morning, perhaps due to momentum trading. Great dividend. Hold, but probably not a Top Pick today.
Paul MacDonaldOwned
0
Premium contentPAST TOP PICK
COMMENT
BUY
Loves it. Looks fantastic, should be in your portfolio. Model price of $216.72, 60% upside. Yield is 3.85%.
Brian Acker, CAOwned
0
Premium contentTOP PICK
COMMENT
Hitting a 52-week high today. If your shares have run like Jim Cramer's have since 2019, then sure take some profits. That's fine, but his own position is smaller and he's hanging on.
Joe TerranovaOwned
0
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20scale(-1,%201)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
